Jump to content
Powered by
  • Industry report The healthcare industry – the innovation driver of the 21st century: opportunities and challenges

    BIOPRO Baden-Württemberg’s new industry report entitled "The Healthcare Industry 2018: Facts and Figures for Baden-Württemberg" has just been published in both German and English.

  • Publications Selected publications

    Here you can find selected publications on the Baden-Württemberg healthcare industry.

  • Contact Stay in touch

    Would you like continue receiving e-mail notifications about our activities, up-to-date information, events, opportunities for cooperation and general industry information? Register here to stay informed about current issues.

  • Dossier Immunology – at the forefront of medical progress

    Immunological approaches are central to everything – learn more!

Register now!

Online event
Registration deadline:

Brandnew & virtual: We make cross-border networking and business initiation possible for you! In collaboration with virtual.MEDICA 2020 and the Enterprise Europe Network (EEN), bw-i organizes a digital networking forum in the healthcare sector. We are supported by various partners in the healthcare sector, including BIOPRO Baden-Württemberg.

Register now!

Online
Registration deadline:

Focusing on novel therapeutic and diagnostic immunological approaches to fight cancer, our 18. joint event with BioValley France will take place on the 3rd of December, 2020 in Strasbourg. Apply for a short presentation!

Latest news

  • Atriva Therapeutics - 21/10/2020

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

  • Press release - 20/10/2020

    The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19.

  • Press release - 15/10/2020

    Tumors of the pancreas are particularly feared. They are usually discovered late and mortality is high. Until now, no targeted and personalized therapies exist. Scientists at the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine* (HI-STEM) have now succeeded for the first time in defining two differently aggressive molecular subtypes of pancreatic carcinoma.

  • Press release - 15/10/2020

    International study in which Freiburg scientists are participating maps molecular targets for possible therapy for MERS, SARS-CoV1, and SARS-CoV2.

  • Article - 14/10/2020

    If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

Website address: https://www.gesundheitsindustrie-bw.de/en